Vantage Consulting Group’s Organogenesis Holdings ORGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-21,123
Closed -$56.8K 235
2022
Q4
$56.8K Buy
21,123
+2,678
+15% +$7.81K 0.03% 210
2022
Q3
$60K Buy
18,445
+7,923
+75% +$35.8K 0.04% 205
2022
Q2
$51K Buy
+10,522
New +$64.8K 0.03% 209

Other funds holding ORGO

Vantage Consulting Group's ORGO Position: Q1 2023 in Review

Vantage Consulting Group sold out of Organogenesis Holdings (ORGO) in Q1 2023, closing a stake of 21,123 shares — an estimated $56.8K sold.

Vantage Consulting Group first reported a position in ORGO in Q2 2022 and held it in 3 quarters. The position peaked at $60K in Q3 2022. 131 funds tracked by Wall St. Rank hold ORGO as of Q1 2023.

  • Vantage Consulting Group reported no remaining Organogenesis Holdings position as of Q1 2023 after selling out during the quarter.
  • Vantage Consulting Group sold 21,123 Organogenesis Holdings shares in Q1 2023, an estimated $56.8K.
  • Vantage Consulting Group first reported a position in Organogenesis Holdings in Q2 2022 and held it in 3 quarters.
  • Vantage Consulting Group's Organogenesis Holdings position peaked at $60K in Q3 2022.
  • 131 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2023.

Based on Vantage Consulting Group's 13F filing for Q1 2023, filed 10 May 2023.